Valeant Weighs New Viramidine Dosing After Phase III Stumble
This article was originally published in The Pink Sheet Daily
Executive Summary
Prediction of a 2007 launch is unaltered by failure of first pivotal hepatitis C trial to meet one of two co-primary endpoints.
You may also be interested in...
After Second Stumble With Viramidine Pivotal Trial, Valeant Falls Back to Phase II
Company will reconsider dosing for its hepatitis C candidate.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.